Machine learning models identify immunophenotypes in NSCLC for immunotherapy guidance

NewsGuard 100/100 Score

A new study examines the development of two machine learning models to classify the immunophenotype of a cancer specimen. The digital pathology approach presented can characterize and classify cancer immunophenotypes in a reproducible and scalable fashion, holding promise for the application of such a. method to identify patients that may benefit from immunotherapy in non-small cell lung cancer (NSCLC), according to the study published in the peer-reviewed journal AI in Precision Oncology. 

The cellular composition of the tumor immune microenvironment is a key contributor to the response of the tumor to immunotherapy. TGF-ß signaling is known to promote immune-exclusion, where CD8+ T cells are in the surrounding stromal tissue but not within the tumor itself.

To better identify patients who are immune-excluded, Rui Wang, from Sanofi, and coauthors, developed two machine learning models to quantify CD8+ cell positivity and classify the immunophenotype of a cancer specimen in patients with NSCLC.

"Our results support the potential use of machine learning-predicted cancer immunophenotypes to identify patients that may benefit from immunotherapy and/or TGF-ß blockage in NSCLC," concluded the investigators.

This research points towards improvements in patient identification for drug candidacy, utilizing AI and machine learning to pinpoint precise biomarkers for immunotherapy in NSCLC. It signifies progress towards personalized medicine, promising treatments tailored to individual patient profiles for greater effectiveness and minimized side effects. Essentially, it emphasizes the importance of directing new treatments to the right patients, paving the way for a new era of precision in cancer care."

Douglas Flora, MD, Editor-in-Chief of AI in Precision Oncology

Journal reference:

Pomponio, R. J., et al. (2024) Classification of the Tumor Immune Microenvironment Using Machine-Learning-Based CD8 Immunophenotyping As a Potential Biomarker for Immunotherapy and TGF-β Blockade in Nonsmall Cell Lung Cancer. AI in Precision Oncology.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study identifies key protein biomarkers for early detection of pancreatic cancer